Given Imaging soars after filing for Japanese approval

Israel's Given Imaging ($GIVN) saw its stock surge after filing for Japanese approval for its PillCam Colon 2 endoscopic capsule.

Given is filing in Japan on the strength of a pivotal study finding that the PillCam Colon 2 accurately identified 94% of the polyps found through traditional colonoscopy. As a result, shares rose 5.4% to $14.07 on the news, Bloomberg reports. Given's New York stock is now trading at a 52 cent premium over its Tel Aviv shares, according to the news service.

The jump in share value is a welcome respite from the shareholder ire Given faced last month. In August, Given announced it would seek FDA approval for the device, instead of a simpler general-screening indication, and investors punished the company by driving its stock price down to $12.69, a three-year low.

The device is a swallowable pill outfitted with a camera on each end and an LED bulb to light the way. Once ingested, the PillCam Colon 2 records and transmits video at about 35 frames per second with a 10-hour battery life, according to Given.

The PillCam Colon 2 got its CE mark in 2009 and is commercially available in Europe, Latin America, Canada and parts of Asia. Getting approval in Japan will be a huge boost for Given, CEO Homi Shamir said in a statement, with an estimated addressable market of about 1 million procedures each year.

- read Bloomberg's report
- check out Given Imaging's statement

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.